Cystic Fibrosis Foundation

Life expectancy has greatly increased from a predicted survival of 16 years in 1970 to more than 40 years for patients born in the 1990s.5 The average age of patients in the Cystic Fibrosis Foundation Registry is now more than 16 years, and many are living far into adulthood. More than 40% of CF patients in the 2004 Registry annual report are over 18 years old, and the oldest is age 74.13... 

The website http //www.cff.org/ is maintained and updated by the Cystic Fibrosis Foundation. It provides a wealth of data on all aspects of the disease, the patients, science, treatment, and the therapeutic pipeline. 

Jason Kindrachuk is a postdoctoral fellow at the University of British Columbia (UBC) in the laboratory of Professor R. E. W. Hancock. Jason received his Ph.D. from the University of Saskatchewan in 2007 where his research focused on host and pathogen sensory systems. During his study he specially focused on TLR-9 receptor—ligand interactions and the interactions between host defense peptides and the PhoPQ two-component sensory system of Salmonella typhimurium. In 2008 Jason received the Canadian Cystic Fibrosis Foundation Kin Canada Fellowship for his research in the area of alternative therapies for treatment of antibiotic- and multidrug-resistant bacteria. Currently his research is focused on the investigation of structure-activity relationships amongst natural and synthetic host defense peptides from the perspective of associated immunomodulatory activities and as well as vaccine formulation strategies. 

The work in the laboratory was supported by MRC of Canada and the Canadian Cystic Fibrosis Foundation... 

Acknowledgments The author s studies mentioned in this review were supported by grants from the University of North Carolina Research Council, the North American Cystic Fibrosis Foundation, and the National Institute of Heath (NIDDK). 

Cystic Fibrosis Foundation. CFF Patient Registry. Patient Registry Annual Data Report 2007. Bethesda, Maryland (2009). 

Research on CETR trafficking in the Thomas lab is supported by grants from Cystic Fibrosis Foundation Therapeutics, Inc., and the Canadian Institutes of Health Research. H.M.S. is supported by a fellowship from the Canadian Cystic Fibrosis Foundation. 

The United States Cystic Fibrosis Foundation (CFF) states that the diagnosis of CF is based on the following criteria ... 

Cystic Fibrosis Foundation Center Directors Update 1. Bethesda, MD, Cystic Fibrosis Foundation (http //vrww.cff.org), 1993... 

Cystic Fibrosis Foundation. Patient registry 1999. Annual data report. Bethesda, Md, September 2000. 

Financial supports from the National Cancer Institute/National Institutes of Health and the Cystic Fibrosis Foundation are greatly appreciated. 

Grants from the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council, and the Canadian Cystic Fibrosis Foundation support research in the author s laboratory. The author holds a Canada Research Chair in Infectious Diseases and Microbial Pathogenesis. 

This work was supported by the Canadian Cystic Fibrosis Foundation. The author is grateful for the invaluable help of John Schutzbach. 

An expert group convened by the Cystic Fibrosis Foundation Consensus Conference found no scientific evidence that Gastrografin was superior to other low osmolar water-soluble contrast media in the... 

Support for this research by the Northeast Ohio Chapter of the Cystic Fibrosis Foundation is gratefully acknowledged. 

Author royalties from this book are being donated to the Cystic Fibrosis Foundation. 

Paradoxically, this high prevalence of children with special health care needs is related to advances in medical science, which have greatly increased survival rates for a number of health conditions. For example, the median survival age for children with cystic fibrosis has more than doubled in the last 3 decades, up fi om 11 years in 1966 to 29 years in 1993 (Cystic Fibrosis Foundation, 1994). Similarly, acute lymphoblastic leukemia (all), a disease that was once almost uniformly fatal, now has an average childhood survival rate of 5 years or more (Mulhern ... 

This work was supported by grants from the National Institutes of Health (POl HL59407-03 and P30 DK47757-09), Cystic Fibrosis Foundation and Juvenile Diabetes Research Foundation. The author holds equity in Targeted Genetics Corp., Seattle, Washington. 

Research described in this chapter was in part supported by National Instimtes of Health (NIH) grant HL58340 (J.F.E. and D.D.), the Center for Gene Therapy funded by NIH (P30 DK54759) (J.F.E.) and the Cystic Fibrosis Foundation, and... 

The authors thank Miriam Kelly and Carolyn Coyne for their assistance with figures and Marguerite Applin for clerical assistance. This work was supported by HL58342 (LGJ) and HL51818 (RCB) from the National Heart Lung and Blood Institute, National Institutes of the Health and a grant (S880) from the Cystic Fibrosis Foundation. 

This work was supported by grants fiom the NHLBI (HL51811, HL59412), the NIDDK (DK51809, DK58327), the Cystic Fibrosis Foundation and the Alpha One Foundation. 

---